KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC

May 29-June 2, 2015; Chicago, Illinois
In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.
Format: Microsoft PowerPoint (.ppt)
File Size: 423 KB
Released: June 1, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Downloadable summary slideset of key takeaways from a live CCO Webinar focused on immune checkpoint inhibition for the treatment of advanced SCLC.

Anna F. Farago, MD, PhD Taofeek K. Owonikoko, MD, PhD Released: July 15, 2020

Gain key clinical insights fast, with this short slideset from CCO on biomarkers for imuno-onolcogy approaches across solid tumors

Jamie E. Chaft, MD John L. Marshall, MD Scot Niglio, MD Released: July 15, 2020

A short slideset from Clinical Care Options covering key clinical updates and strategies for the current management of advanced Lung and GI cancers

person default Mary Jo Fidler, MD John L. Marshall, MD Released: July 13, 2020

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?